• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
77,766.34 264.22
( 0.34%)
Global Indices
Nasdaq
52,909.39 583.15
(1.11%)
Dow Jones
7,503.05 -1.18
(-0.02%)
Hang Seng
69,733.68 1,000.53
(1.46%)
Nikkei 225
10,664.80 186.46
(1.78%)
Forex
USD-INR
94.99 0.39
(0.42%)
EUR-INR
108.21 0.30
(0.28%)
GBP-INR
125.93 0.66
(0.53%)
JPY-INR
0.58 0.00
(0.27%)

EQUITY - MARKET SCREENER

Natco Pharma Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
524816
INE987B01026
477.507017
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
NATCOPHARM
13.05
16725.28
EPS(TTM)
Face Value()
Div & Yield %
71.55
2
0.54
 

Bombay Dyeing Q4 PAT jumps 82% YoY to Rs 21 cr
May 09,2026

Revenue from operations increased 10.3% year-on-year to Rs 395.84 crore for the quarter ended 31 March 2026.

Total expenses declined 11.17% year-on-year to Rs 362.43 crore during the quarter. The cost of raw materials fell 26.78% to Rs 204.10 crore, while employee benefit expenses surged 451.07% YoY to Rs 48.99 crore.

On a segmental basis, polyester revenue stood at Rs 367.05 crore (up 11.45% YoY), while the real estate business stood at Rs 18.70 crore (down 8.65% YoY) and revenue from the retail / textile segment stood at Rs 6.84 crore (down 25.65% YoY) during the period under review.

On a full-year basis, the company’s consolidated net profit tanked 94.5% to Rs 26.92 crore on a 9% decline in net sales to Rs 1,460.33 crore in FY26 over FY25.

Bombay Dyeing & Manufacturing Company is currently engaged in the business of real estate development, polyester staple fiber, and retail (textiles).

The scrip shed 0.26% to end at Rs 135.60 on Friday, 8 May 2026.